Lu-177 PSMA vs Comparator Treatments and Survival in Metastatic Castration-Resistant Prostate Cancer
Findings of this secondary analysis of the TheraP and VISION randomized clinical trials suggest that the choice of comparator treatments (ie, cabazitaxel vs PPT) may explain the difference in the observed effect of Lu-177 PSMA on OS between the 2 trials. Causal inference methods such as RPSFTM and IPCW may help rule out crossover as a plausible explanation.
Authors
- Ian C. Marschner (ORCID: https://orcid.org/0000-0002-6225-1572)
- Andrew Martin (ORCID: https://orcid.org/0000-0001-5804-2295)
- Yu Yang Soon (ORCID: https://orcid.org/0000-0002-1995-2170)
- Louise Emmett (ORCID: https://orcid.org/0000-0002-4895-7384)
- Martin R. Stockler (ORCID: https://orcid.org/0000-0003-3793-8724)
- Michael S. Hofman (ORCID: https://orcid.org/0000-0001-8622-159X)
- Ian D. Davis (ORCID: https://orcid.org/0000-0002-9066-8244)
- Manjula Schou
Institutions
- The University of Sydney (AU)
- The University of Queensland (AU)
- The University of Melbourne (AU)
- National University of Singapore (SG)
- Concord Repatriation General Hospital (AU)
- Peter MacCallum Cancer Centre (AU)
- UNSW Sydney (AU)
- St Vincent's Hospital Sydney (AU)
- Chris O’Brien Lifehouse (AU)
- Eastern Health (AU)
- National University Cancer Institute, Singapore (SG)
- National Health and Medical Research Council (AU)
- Monash University (AU)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1001/jamanetworkopen.2024.33863
- Citations
- 7
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 2.93